Research programme: sublingual spray therapeutics - INSYS Therapeutics

Drug Profile

Research programme: sublingual spray therapeutics - INSYS Therapeutics

Alternative Names: Diclofenac sublingual spray - INSYS; Ketorolac sublingual spray - INSYS; Sildenafil sublingual spray - INSYS; Supportive care sublingual spray - INSYS

Latest Information Update: 18 Oct 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class 2 ring heterocyclic compounds; Carbazoles; Cyclopropanes; Imidazoles; Morphinans; Non-opioid analgesics; Opioid analgesics; Phenyl ethers; Phenylacetates; Piperazines; Purines; Small molecules; Sulfones
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors; Cyclooxygenase inhibitors; Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Erectile dysfunction; Musculoskeletal pain; Pain

Most Recent Events

  • 29 Feb 2016 Preclinical development of Diclofenac, Ketorolac, and Sildenafil sublingual sprays is ongoing in USA (INSYS Therapeutics Form 10-K, February 2016)
  • 01 Jan 2014 Preclinical trials in Erectile dysfunction in USA (Sublingual)
  • 01 Jan 2014 Preclinical trials in Musculoskeletal pain in USA (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top